Direct Coombs' tests for IgG and C3 were performed before and after erythrocyte transfusion to determine potential in vivo binding of circulating immune complexes. Thus in eight of 14 experiments, in which erythrocytes carried no IgG before packed erythrocyte transfusion, seven became Coombs' positive for IgG after the transfusion. In seven of 14 experiments, in which erythrocytes were negative for complement before transfusion, five became positive afterwards. Moreover, in 12 instances slight increases of CR1 activity of patients' erythrocytes were observed within eight days, which improved further within 35 days after erythrocyte transfusion. These studies suggest that transfusion of erythrocytes with high CR1 activity results in the removal of circulating immune complexes and that this process is dependent on complement consumption. These experiments support the hypothesis that erythrocyte-CR1 has a functional role in the removal of circulating immune complexes and may thereby inhibit the deposition of immune complexes within body tissue constituents.
A number of previous studies have shown that erythrocytes play a major part in the removal of circulating immune complexes via immune adherence receptors (C3b receptor, CR1). Medof et al reported that immune complexes interact preferentially with erythrocytes in vitro rather than with other peripheral cells bearing CR1. 1 Recently, several studies concerning CR1 of erythrocytes in patients with immune complex related diseases were reported.-lo Thus two reports on patients with systemic lupus erythematosus showed a decrease in CR1 binding activity associated with an increase in disease activity. 8 
was measured before and after packed erythrocyte transfusion (Fig. 3) . In all 14 experiments abnormal CR1 binding activity was present before erythrocyte transfusion. Receptor activity was absent in four and the others had defective activity ranging from + to ++ (normal CR1 activity is ++++).
After erythrocyte transfusion we observed slight increases of CR1 activity within the first five days. lating immune complex decrease in 11 instances with initial CH50 titres ranging from 21 to 44 units/ml (Fig. 2) . Striking decreases were observed in patients with CH50 titres greater than 35 CH50 units/ml. On the other hand, no decreases of complement concentration occurred in three patients with low CH50 titres ranging from 1 to 10 units/ml (closed arrows) at the onset. After the disappearance of the circulating immune complexes complement concentrations increased to the initial ranges or higher during the second period. In one experiment, in which the circulating immune complexes persisted into the six to 35 day period (open arrow, Fig. 1 ), the complement concentration continued to decrease. (Fig. 4) .
Of eight patients whose erythrocytes were negative for IgG (two patients with type III and six patients with negative Coombs' tests), seven 
In contrast, in erythrocytes consecutively exposed to the same amount of heat aggregated human IgG in the absence of complement (human serum heated at 56°C for 30 minutes) haemagglutination patterns did not diminish even after the 18th exposure.
Discussion
The ability to remove soluble immune complexes by transfused blood products was first reported by Safai-Kutti et al, who showed that platelet transfusions resulted in the removal of soluble immune complexes from the circulation.'6 This observation was attributed to the Fc receptors of the transfused platelets rather than to the dilution effects of transfusions. A number of previous studies have shown that erythrocyte-CR1 is able to bind circulating immune complexes in vivo. 12 17 Such binding, which is complement dependent, results in diminished CR1 activity and in the appearance of positive direct Coombs' tests.12
Medof et al reported that erythrocytes isolated after the binding and release of immune complexes by C3 inactivator would again bind newly formed immune complexes with the same rapidity and capacity as fresh erythrocytes,' suggesting that receptor activity was not altered by the binding and subsequent release of immune complexes. These conclusions were based on observations using only one exposure of immune complexes to intact CR1, however. Our in vitro experiments showed that CR1 activity, although not altered by limited binding and release of immune complexes (Fig. 5) , nevertheless gradually decreased after subsequent consecutive exposures to immune complex-complement complexes. The normal serum concentration of C3 inactivator has been determined as approximately 53 ,ug/ml.18 In another study only 2 [tg/ml of purified C3 inactivator with purified CR1 (100 ,ug/ml:equivalent to 2*5 x 108 erythrocytes/ml) released approximately 75% of labelled C3 as the C3c fragment from erythrocyte-antibody-complement 1423b complexes. 1In our repetitive binding experiment a 1:15 dilution of human serum as a source of complement would have had no more than 3-5 tig/ml of C3
inactivator. This quantity appears to be enough to release C3c molecules from CR1 in the presence of 2*25x 108 erythrocytes/ml (1-5% 
